Compare RANI & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RANI | PMVP |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.6M | 72.2M |
| IPO Year | 2021 | 2020 |
| Metric | RANI | PMVP |
|---|---|---|
| Price | $0.54 | $1.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $7.20 | $4.00 |
| AVG Volume (30 Days) | ★ 495.4K | 436.5K |
| Earning Date | 11-17-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.14 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,633,000.00 | N/A |
| Revenue This Year | $283.19 | N/A |
| Revenue Next Year | $5.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 58.85 | N/A |
| 52 Week Low | $0.55 | $1.02 |
| 52 Week High | $2.16 | $1.91 |
| Indicator | RANI | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 31.80 | 44.52 |
| Support Level | N/A | $1.24 |
| Resistance Level | $0.85 | $1.38 |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 17.67 | 47.06 |
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.